Get your free ETF data sample from our comprehensive offerings. Start your free trial→
Help us improve your experience. Please confirm your investor type:
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
ETFs with exposure to Viking Therapeutics, Inc. (VKTX)
4.62% | +3.78% | -5.57% | +€2.5M | +€12M | €47M | 0.59% | Not rated | |
2.08% | +5.42% | +1.56% | €0 | +€1.3M | €3.8M | 0.59% | Not rated | |
State Street SPDR S&P Biotech ETF - USD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 1.03% | +17.25% | +28.43% | +€768M | +€464M | €9.3B | 0.35% | |
Samsung KODEX SYNTH-US Biotech ETF - KRW This ETF provides exposure to Equally Weighted US Biotechnology Equities | 1.01% | +19.61% | +37.30% | €0 | -€69K | €16M | 0.25% | Not rated |
Global X S&P Biotech ETF - AUD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 1.01% | +21.23% | +23.84% | +€925K | +€212K | €31M | 0.45% | Not rated |
WisdomTree BioRevolution UCITS ETF Acc – USD This ETF provides exposure to Equally Weighted Developed markets Equities | 0.86% | +13.99% | +22.55% | +€2.4M | +€7.5M | €18M | 0.45% | |
WisdomTree BioRevolution Fund - USD This ETF provides exposure to Other Developed markets Equities | 0.85% | +14.02% | +22.09% | €0 | -€309K | €2.4M | 0.45% | Not rated |
Virtus LifeSci Biotech Clinical Trials ETF - USD This ETF provides exposure to Equally Weighted US Equities | 0.65% | +17.61% | +33.41% | +€475K | +€6.2M | €45M | 0.65% | |
0.51% | +7.35% | +2.70% | -€649K | -€1.9M | €48M | 0.99% | Not rated | |
Research Affiliates Deletions ETF - USD This ETF provides exposure to Equally Weighted Mid and Small-Cap US Equities | 0.51% | +2.94% | +24.73% | -€14M | -€2.1M | €35M | 0.39% | Not rated |
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
